Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.31
COV's Cash to Debt is ranked higher than
56% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.07 vs. COV: 0.31 )
COV' s 10-Year Cash to Debt Range
Min: 0.11   Max: 0.49
Current: 0.31

0.11
0.49
Equity to Asset 0.49
COV's Equity to Asset is ranked higher than
61% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. COV: 0.49 )
COV' s 10-Year Equity to Asset Range
Min: 0.34   Max: 0.61
Current: 0.49

0.34
0.61
Interest Coverage 9.76
COV's Interest Coverage is ranked higher than
60% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.42 vs. COV: 9.76 )
COV' s 10-Year Interest Coverage Range
Min: 2.33   Max: 66.5
Current: 9.76

2.33
66.5
F-Score: 8
Z-Score: 3.73
M-Score: -2.52
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 18.69
COV's Operating margin (%) is ranked higher than
89% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. COV: 18.69 )
COV' s 10-Year Operating margin (%) Range
Min: 4.31   Max: 26.05
Current: 18.69

4.31
26.05
Net-margin (%) 15.59
COV's Net-margin (%) is ranked higher than
91% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.64 vs. COV: 15.59 )
COV' s 10-Year Net-margin (%) Range
Min: -3.26   Max: 17.95
Current: 15.59

-3.26
17.95
ROE (%) 17.24
COV's ROE (%) is ranked higher than
90% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.72 vs. COV: 17.24 )
COV' s 10-Year ROE (%) Range
Min: -4.32   Max: 20.42
Current: 17.24

-4.32
20.42
ROA (%) 8.23
COV's ROA (%) is ranked higher than
85% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.87 vs. COV: 8.23 )
COV' s 10-Year ROA (%) Range
Min: -2.05   Max: 9.3
Current: 8.23

-2.05
9.3
ROC (Joel Greenblatt) (%) 53.07
COV's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.54 vs. COV: 53.07 )
COV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 9.91   Max: 98.7
Current: 53.07

9.91
98.7
Revenue Growth (3Y)(%) 0.10
COV's Revenue Growth (3Y)(%) is ranked higher than
65% of the 262 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. COV: 0.10 )
COV' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 9.2
Current: 0.1

0
9.2
EBITDA Growth (3Y)(%) -2.00
COV's EBITDA Growth (3Y)(%) is ranked higher than
67% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.30 vs. COV: -2.00 )
COV' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 50.9
Current: -2

0
50.9
EPS Growth (3Y)(%) -1.20
COV's EPS Growth (3Y)(%) is ranked higher than
68% of the 219 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. COV: -1.20 )
COV' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 21.9
Current: -1.2

0
21.9
» COV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

COV Guru Trades in Q4 2013

Ray Dalio 80,858 sh (New)
Jeremy Grantham 1,224,091 sh (+116.92%)
Steven Cohen 32,119 sh (+45.62%)
Vanguard Health Care Fund 4,994,700 sh (+24.79%)
Ronald Muhlenkamp 181,635 sh (+4.02%)
Robert Olstein 94,500 sh (+3.85%)
Mario Gabelli 622,152 sh (+1.52%)
Pioneer Investments 3,017,822 sh (+0.95%)
Dodge & Cox 111,317 sh (unchged)
Yacktman Focused Fund 800,000 sh (unchged)
Bill Nygren 2,708,000 sh (unchged)
Steven Romick 4,851,700 sh (unchged)
Jean-Marie Eveillard 1,500 sh (unchged)
Yacktman Fund 850,000 sh (unchged)
Jim Simons Sold Out
Joel Greenblatt Sold Out
Donald Yacktman 1,790,375 sh (-0.31%)
First Pacific Advisors 5,346,800 sh (-0.74%)
Manning & Napier Advisors, Inc 80,770 sh (-6.02%)
Private Capital 244,555 sh (-36.57%)
HOTCHKIS & WILEY 657,000 sh (-46.79%)
John Keeley 44,520 sh (-52.66%)
» More
Q1 2014

COV Guru Trades in Q1 2014

Louis Moore Bacon 6,022 sh (New)
Joel Greenblatt 3,746 sh (New)
Paul Tudor Jones 289,467 sh (New)
Jeremy Grantham 2,103,588 sh (+71.85%)
HOTCHKIS & WILEY 788,400 sh (+20%)
Pioneer Investments 3,131,476 sh (+3.77%)
Yacktman Fund 850,000 sh (unchged)
Steven Romick 4,851,700 sh (unchged)
Jean-Marie Eveillard 1,500 sh (unchged)
Yacktman Focused Fund 800,000 sh (unchged)
Robert Olstein 94,500 sh (unchged)
Vanguard Health Care Fund 4,994,700 sh (unchged)
Bill Nygren 2,708,000 sh (unchged)
Ronald Muhlenkamp 181,455 sh (-0.1%)
Private Capital 243,820 sh (-0.3%)
Donald Yacktman 1,784,825 sh (-0.31%)
John Keeley 43,770 sh (-1.68%)
First Pacific Advisors 5,184,500 sh (-3.04%)
Dodge & Cox 101,517 sh (-8.8%)
Manning & Napier Advisors, Inc 71,870 sh (-11.02%)
Mario Gabelli 543,560 sh (-12.63%)
Ray Dalio 47,058 sh (-41.8%)
Steven Cohen 6,418 sh (-80.02%)
» More
Q2 2014

COV Guru Trades in Q2 2014

Eric Mindich 446,000 sh (New)
John Paulson 7,000,000 sh (New)
George Soros 227,000 sh (New)
Louis Moore Bacon 126,022 sh (+1992.69%)
Jeremy Grantham 2,776,488 sh (+31.99%)
Mario Gabelli 637,530 sh (+17.29%)
Ronald Muhlenkamp 182,180 sh (+0.4%)
HOTCHKIS & WILEY 788,700 sh (+0.04%)
Jean-Marie Eveillard 1,500 sh (unchged)
Vanguard Health Care Fund 4,994,700 sh (unchged)
Yacktman Focused Fund Sold Out
Manning & Napier Advisors, Inc Sold Out
Ray Dalio Sold Out
Donald Yacktman Sold Out
Robert Olstein Sold Out
Yacktman Fund Sold Out
Joel Greenblatt Sold Out
Private Capital 238,715 sh (-2.09%)
Steven Romick 4,559,929 sh (-6.01%)
John Keeley 40,840 sh (-6.69%)
First Pacific Advisors 4,822,800 sh (-6.98%)
Dodge & Cox 92,017 sh (-9.36%)
Pioneer Investments 1,818,973 sh (-41.91%)
Bill Nygren 160,000 sh (-94.09%)
Paul Tudor Jones 7,416 sh (-97.44%)
» More
Q3 2014

COV Guru Trades in Q3 2014

David Abrams 2,620,000 sh (New)
Paul Singer 502,653 sh (New)
Steven Cohen 45,000 sh (New)
Eric Mindich 3,881,000 sh (+770.18%)
Jeremy Grantham 12,981,012 sh (+367.53%)
John Paulson 12,595,000 sh (+79.93%)
Vanguard Health Care Fund 4,994,700 sh (unchged)
Steven Romick 4,559,929 sh (unchged)
Bill Nygren 160,000 sh (unchged)
John Keeley 40,840 sh (unchged)
Ronald Muhlenkamp 182,180 sh (unchged)
Jean-Marie Eveillard 1,500 sh (unchged)
George Soros Sold Out
Louis Moore Bacon Sold Out
First Pacific Advisors 4,774,600 sh (-1%)
Pioneer Investments 1,770,893 sh (-2.64%)
Dodge & Cox 89,017 sh (-3.26%)
HOTCHKIS & WILEY 727,700 sh (-7.73%)
Mario Gabelli 462,251 sh (-27.49%)
Private Capital 157,828 sh (-33.88%)
Paul Tudor Jones 3,900 sh (-47.41%)
» More
» Details

Insider Trades

Latest Guru Trades with COV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
David Abrams 2014-09-30 New Buy13.4%$82.54 - $91.76 $ 102.916%2620000
John Paulson 2014-09-30 Add 79.93%2%$82.54 - $91.76 $ 102.916%12595000
Private Capital 2014-09-30 Reduce -33.88%0.85%$82.54 - $91.76 $ 102.916%157828
George Soros 2014-09-30 Sold Out 0.15%$82.54 - $91.76 $ 102.916%0
Mario Gabelli 2014-09-30 Reduce -27.49%0.08%$82.54 - $91.76 $ 102.916%462251
John Paulson 2014-06-30 New Buy2.7%$69.03 - $91.24 $ 102.938%7000000
Bill Nygren 2014-06-30 Reduce -94.09%1.51%$69.03 - $91.24 $ 102.938%160000
Robert Olstein 2014-06-30 Sold Out 0.95%$69.03 - $91.24 $ 102.938%0
Yacktman Focused Fund 2014-06-30 Sold Out 0.62%$69.03 - $91.24 $ 102.938%0
Yacktman Fund 2014-06-30 Sold Out 0.56%$69.03 - $91.24 $ 102.938%0
Donald Yacktman 2014-06-30 Sold Out 0.55%$69.03 - $91.24 $ 102.938%0
George Soros 2014-06-30 New Buy0.15%$69.03 - $91.24 $ 102.938%227000
Ray Dalio 2014-06-30 Sold Out 0.03%$69.03 - $91.24 $ 102.938%0
Joel Greenblatt 2014-06-30 Sold Out $69.03 - $91.24 $ 102.938%0
Ray Dalio 2014-03-31 Reduce -41.8%0.02%$66.35 - $72.5 $ 102.948%47058
Joel Greenblatt 2014-03-31 New Buy$66.35 - $72.5 $ 102.948%3746
Private Capital 2013-12-31 Reduce -36.57%0.8%$59.82 - $68.42 $ 102.958%244555
Vanguard Health Care Fund 2013-12-31 Add 24.79%0.22%$59.82 - $68.42 $ 102.958%4994700
HOTCHKIS & WILEY 2013-12-31 Reduce -46.79%0.16%$59.82 - $68.42 $ 102.958%657000
John Keeley 2013-12-31 Reduce -52.66%0.06%$59.82 - $68.42 $ 102.958%44520
Ray Dalio 2013-12-31 New Buy0.04%$59.82 - $68.42 $ 102.958%80858
Joel Greenblatt 2013-12-31 Sold Out 0.03%$59.82 - $68.42 $ 102.958%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Covidien PLC

Steven Romick's Top Five Stocks
Steven Romick is the portfolio manager of First Pacific Advisors Crescent Fund. The fund’s investment objective and strategy reports that they “seek to generate equity-like returns over the long-term, take less risk than the market and avoid permanent impairment of capital.” Read more...
Weekly CFO Sells Highlight: Chicago Bridge and Iron Company, Covidien PLC, Carnival PLC, Google Inc.
According to GuruFocus Insider Data, the recent CFO sales were: Chicago Bridge and Iron Company, Covidien PLC, Carnival PLC, and Google Inc. Read more...
Weekly 52-Week Highs Highlight: COV, EQT, XLNX, TEVA
According to GuruFocus list of 52-week highs, Covidien PLC, EQT Corp, Xilinx Inc. and Teva Pharmaceuticals Industries Ltd. have all reached their 52 week highs. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 28.30
COV's P/E(ttm) is ranked higher than
82% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 41.40 vs. COV: 28.30 )
COV' s 10-Year P/E(ttm) Range
Min: 10.07   Max: 28.51
Current: 28.3

10.07
28.51
P/B 4.62
COV's P/B is ranked higher than
64% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.52 vs. COV: 4.62 )
COV' s 10-Year P/B Range
Min: 1.64   Max: 4.66
Current: 4.62

1.64
4.66
P/S 4.40
COV's P/S is ranked higher than
61% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.80 vs. COV: 4.40 )
COV' s 10-Year P/S Range
Min: 1.25   Max: 4.43
Current: 4.4

1.25
4.43
PFCF 28.35
COV's PFCF is ranked higher than
85% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 56.61 vs. COV: 28.35 )
COV' s 10-Year PFCF Range
Min: 9.51   Max: 213.27
Current: 28.35

9.51
213.27
EV-to-EBIT 25.13
COV's EV-to-EBIT is ranked higher than
77% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.95 vs. COV: 25.13 )
COV' s 10-Year EV-to-EBIT Range
Min: 6.8   Max: 89.9
Current: 25.13

6.8
89.9
PEG 14.15
COV's PEG is ranked higher than
82% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. COV: 14.15 )
COV' s 10-Year PEG Range
Min: 0.37   Max: 6.88
Current: 14.15

0.37
6.88
Shiller P/E 29.72
COV's Shiller P/E is ranked higher than
88% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 143.42 vs. COV: 29.72 )
COV' s 10-Year Shiller P/E Range
Min: 17.76   Max: 29.97
Current: 29.72

17.76
29.97
Current Ratio 1.66
COV's Current Ratio is ranked higher than
55% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.72 vs. COV: 1.66 )
COV' s 10-Year Current Ratio Range
Min: 1.41   Max: 2.52
Current: 1.66

1.41
2.52
Quick Ratio 1.23
COV's Quick Ratio is ranked higher than
59% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. COV: 1.23 )
COV' s 10-Year Quick Ratio Range
Min: 1.16   Max: 1.91
Current: 1.23

1.16
1.91

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.28
COV's Dividend Yield is ranked lower than
54% of the 149 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.45 vs. COV: 1.28 )
COV' s 10-Year Dividend Yield Range
Min: 0.39   Max: 2.51
Current: 1.28

0.39
2.51
Dividend Payout 0.45
COV's Dividend Payout is ranked higher than
79% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. COV: 0.45 )
COV' s 10-Year Dividend Payout Range
Min: 0.16   Max: 0.45
Current: 0.45

0.16
0.45
Dividend growth (3y) 39.80
COV's Dividend growth (3y) is ranked higher than
97% of the 111 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.40 vs. COV: 39.80 )
COV' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 66.6
Current: 39.8

0
66.6
Yield on cost (5-Year) 3.80
COV's Yield on cost (5-Year) is ranked higher than
76% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.63 vs. COV: 3.80 )
COV' s 10-Year Yield on cost (5-Year) Range
Min: 1.14   Max: 7.33
Current: 3.8

1.14
7.33
Share Buyback Rate 2.80
COV's Share Buyback Rate is ranked higher than
94% of the 234 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.30 vs. COV: 2.80 )
COV' s 10-Year Share Buyback Rate Range
Min: 0   Max: -0.5
Current: 2.8

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.98
COV's Price/DCF (Projected) is ranked higher than
81% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.67 vs. COV: 1.98 )
COV' s 10-Year Price/DCF (Projected) Range
Min: 1.16   Max: 1.69
Current: 1.98

1.16
1.69
Price/Median PS Value 2.12
COV's Price/Median PS Value is ranked higher than
54% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.19 vs. COV: 2.12 )
COV' s 10-Year Price/Median PS Value Range
Min: 0.83   Max: 1.81
Current: 2.12

0.83
1.81
Earnings Yield (Greenblatt) 4.00
COV's Earnings Yield (Greenblatt) is ranked higher than
76% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.70 vs. COV: 4.00 )
COV' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.1   Max: 14.8
Current: 4

1.1
14.8
Forward Rate of Return (Yacktman) 7.59
COV's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 167 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.14 vs. COV: 7.59 )
COV' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 7.6   Max: 36.7
Current: 7.59

7.6
36.7

Analyst Estimate

Sep15 Sep16 Sep17
Revenue(Mil) 11,087 11,554 12,056
EPS($) 4.33 4.68 4.67
EPS without NRI($) 4.33 4.68 4.67

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, TMO, COO, ISRG » details
Traded in other countries:6COP.Germany,
Covidien PLC formerly known as Covidien Ltd. was incorporated in Bermuda in 2000 as a wholly-owned subsidiary of Tyco International Ltd. In June 2009, Covidien plc announced that one of its subsidiaries has completed the acquisition of VNUS Medical Technologies, Inc. In September 2009, the Company completed the acquisition of Power Medical Interventions Inc. In November 2009, the Company completed the acquisition of Aspect Medical Systems Inc. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. Its products are found in almost every hospital in the United States. Its mission is to create and deliver innovative healthcare solutions, developed in ethical collaboration with medical professionals. It operates through two segments: Medical Devices and Medical Supplies. The Medical Devices segment includes the development, manufacture and sale of endomechanical instruments, energy devices, soft tissue repair products, vascular products, oximetry and monitoring products, airway and ventilation products, and other medical products. The Medical Supplies segment includes the development, manufacture and sale of nursing care products, medical surgical products, SharpSafety products and original equipment manufacturer products. Competitors of Medical Devices segment include diversified healthcare companies, such as Johnson & Johnson, Boston Scientific, Baxter and C.R. Bard. Its Nursing Care products include: Curity and Kerlix and Medical Surgical products include: Medi-Trace. The Company holds more than 13,000 patents and have over 10,500 patent applications pending in the United States and in certain other countries that relate to aspects of the technology used in many of its products. The Company is subject to numerous federal, state and local environmental protection and health and safety laws and regulations both within and outside the United States.
» More Articles for COV

Headlines

Articles On GuruFocus.com
I think Zimmer Will Outperform S&P 500 Performance Dec 04 2014 
Dividend Aristocrats In Focus Part 44: Medtronic Nov 23 2014 
Third Avenue's Top Stocks as of Q3 Nov 16 2014 
Medical Technology Company Offers Investment Opportunity Sep 25 2014 
Gabelli Value 25 Fund Second Quarter Commentary Sep 15 2014 
Paulson, Mindich and Soros Bought Covidien; Should You? Sep 11 2014 
Abbott: A Brighter Future Aug 28 2014 
A Strong Candidate for Investor´s Portfolios Aug 12 2014 
The Gabelli Equity Income Fund Second Quarter 2014 Shareholder Commentary Jul 25 2014 
Steven Romick's Top Five Stocks Jul 11 2014 


More From Other Websites
Farallon Capital ups stake in Covidien Dec 19 2014
Covidien Declares Quarterly Cash Dividend Dec 19 2014
Covidien Declares Quarterly Cash Dividend Dec 19 2014
Great Stocks: Mallinckrodt Rebounds, But Is It A Buy? Dec 18 2014
New Study Shows Addition of Stent Thrombectomy More Effective Than Traditional Pharmaceutical... Dec 17 2014
New Study Shows Addition of Stent Thrombectomy More Effective Than Traditional Pharmaceutical... Dec 17 2014
New Study Shows Addition of Stent Thrombectomy More Effective Than Traditional Pharmaceutical... Dec 17 2014
Covidien’s Unique Capsule Endoscopy PillCam® SB Featured in New Smithsonian Exhibit ‘Tools:... Dec 17 2014
Covidien’s Unique Capsule Endoscopy PillCam® SB Featured in New Smithsonian Exhibit ‘Tools:... Dec 17 2014
Magnetar sells stakes in Covidien Dec 15 2014
Announcement under Irish Takeover Rules Relevant Securities in Issue – December 11, 2014 Dec 11 2014
Announcement under Irish Takeover Rules Relevant Securities in Issue – December 11, 2014 Dec 11 2014
Announcement under Irish Takeover Rules Relevant Securities in Issue – December 11, 2014 Dec 11 2014
Covidien Loses $176M Award in Patent Case Against JNJ Unit Dec 09 2014
Announcement under Irish Takeover Rules Relevant Securities in Issue – December 9, 2014 Dec 09 2014
Announcement under Irish Takeover Rules Relevant Securities in Issue – December 9, 2014 Dec 09 2014
Announcement under Irish Takeover Rules Relevant Securities in Issue – December 9, 2014 Dec 09 2014
Top Global Stocks: Jazz, Actavis In IBD's World List Dec 08 2014
Medtronic-Covidien Deal Nears Finish Line, Approvals Flow In Dec 08 2014
Form 8.1 – Covidien Dec 05 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK